Novo Nordisk: A Pure Play In The Large And Lucrative Diabetes Care Sector

"The Danish drug maker's prolific cash flow and ample borrowing capacity also afford management considerable flexibility, in terms of boosting growth and earnings through both internal and extraordinary activities. (As we've noted in previous reports, Novo undoubtedly represents a potential, if not ideal, suitor or marketing partner for MannKind.) All in all, Novo Nordisk stock looks attractive for the pull to late decade, especially on a risk-adjusted basis."

http://seekingalpha.com/article/1562002-novo-nordisk-a-pure-play-in-the-large-and-lucrative-diabetes-care-sector?source=feed